-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded to Hold by StockNews.com
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded to Hold by StockNews.com
StockNews.com upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM – Get Rating) from a sell rating to a hold rating in a report published on Friday.
A number of other analysts also recently weighed in on the company. Robert W. Baird decreased their price objective on Tandem Diabetes Care to $76.00 in a report on Tuesday, August 9th. Cowen decreased their price objective on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Cowen decreased their price target on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Wells Fargo & Company downgraded Tandem Diabetes Care from an overweight rating to an underweight rating and decreased their price target for the stock from $82.00 to $49.00 in a report on Tuesday, August 9th. Finally, Lake Street Capital decreased their price target on Tandem Diabetes Care from $200.00 to $150.00 in a report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Hold and a consensus target price of $103.36.
Get Tandem Diabetes Care alerts:Tandem Diabetes Care Stock Performance
NASDAQ TNDM opened at $47.42 on Friday. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of -215.55 and a beta of 0.95. Tandem Diabetes Care has a twelve month low of $42.90 and a twelve month high of $155.86. The stock has a fifty day simple moving average of $54.59 and a 200 day simple moving average of $74.56. The company has a quick ratio of 5.36, a current ratio of 6.00 and a debt-to-equity ratio of 0.63.
Institutional Trading of Tandem Diabetes Care
Several large investors have recently made changes to their positions in the company. Fifth Third Bancorp lifted its position in Tandem Diabetes Care by 358.3% in the 2nd quarter. Fifth Third Bancorp now owns 440 shares of the medical device company's stock valued at $26,000 after acquiring an additional 344 shares in the last quarter. Quadrant Capital Group LLC lifted its position in Tandem Diabetes Care by 244.7% in the 2nd quarter. Quadrant Capital Group LLC now owns 517 shares of the medical device company's stock valued at $31,000 after acquiring an additional 367 shares in the last quarter. Exane Derivatives bought a new position in Tandem Diabetes Care in the 1st quarter valued at about $33,000. Byrne Asset Management LLC bought a new position in Tandem Diabetes Care in the 4th quarter valued at about $34,000. Finally, CI Investments Inc. lifted its position in Tandem Diabetes Care by 10,566.7% in the 1st quarter. CI Investments Inc. now owns 320 shares of the medical device company's stock valued at $37,000 after acquiring an additional 317 shares in the last quarter. 95.28% of the stock is currently owned by institutional investors and hedge funds.Tandem Diabetes Care Company Profile
(Get Rating)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Stories
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM – Get Rating) from a sell rating to a hold rating in a report published on Friday.
斯托克新闻网在周五发布的一份报告中将串联糖尿病护理公司(纳斯达克：TNDM-GET评级)的股票评级从卖出评级上调至持有评级。
A number of other analysts also recently weighed in on the company. Robert W. Baird decreased their price objective on Tandem Diabetes Care to $76.00 in a report on Tuesday, August 9th. Cowen decreased their price objective on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Cowen decreased their price target on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Wells Fargo & Company downgraded Tandem Diabetes Care from an overweight rating to an underweight rating and decreased their price target for the stock from $82.00 to $49.00 in a report on Tuesday, August 9th. Finally, Lake Street Capital decreased their price target on Tandem Diabetes Care from $200.00 to $150.00 in a report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Hold and a consensus target price of $103.36.
其他一些分析师最近也加入了对该公司的看法。罗伯特·W·贝尔德在8月9日星期二的一份报告中将他们的串联糖尿病护理价格目标下调至76.00美元。考恩在8月4日星期四的一份报告中将他们的串联糖尿病护理价格目标从141.00美元下调至107.00美元。考恩在8月4日星期四的一份报告中将他们的串联糖尿病护理目标价从141.00美元下调至107.00美元。在8月9日星期二的一份报告中，富国银行将Tandem糖尿病护理公司的评级从增持下调至减持，并将该股的目标价从82.00美元下调至49.00美元。最后，Lake Street Capital在8月4日星期四的一份报告中将Tandem糖尿病护理的目标价格从200.00美元下调至150.00美元。一名投资分析师对该股的评级为卖出，三名分析师给出了持有评级，四名分析师对该公司给予了买入评级。根据MarketBeat.com的数据，该公司目前的平均评级为持有，共识目标价为103.36美元。
Tandem Diabetes Care Stock Performance
串联糖尿病护理股票表现
NASDAQ TNDM opened at $47.42 on Friday. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of -215.55 and a beta of 0.95. Tandem Diabetes Care has a twelve month low of $42.90 and a twelve month high of $155.86. The stock has a fifty day simple moving average of $54.59 and a 200 day simple moving average of $74.56. The company has a quick ratio of 5.36, a current ratio of 6.00 and a debt-to-equity ratio of 0.63.
纳斯达克TNDM上周五开盘报47.42美元。该公司市值为30.5亿美元，市盈率为-215.55，贝塔系数为0.95.Tandem糖尿病护理公司的12个月低点为42.9美元，12个月高位为155.86美元。该股的50日简单移动均线为54.59美元，200日简单移动均线为74.56美元。该公司的速动比率为5.36，流动比率为6.00，债务权益比率为0.63。
Institutional Trading of Tandem Diabetes Care
串联糖尿病护理的制度性交易
Tandem Diabetes Care Company Profile
Tandem糖尿病护理公司简介
(Get Rating)
(获取评级)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Tandem糖尿病护理公司是一家医疗设备公司，为美国和国际上的胰岛素依赖型糖尿病患者设计、开发和销售各种产品。该公司的旗舰产品是T：SILM X2胰岛素输送系统，这是一个由T：SILM X2泵、300个单位的一次性胰岛素盒和输液器组成的泵平台。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 免费获取StockNews.com关于串联糖尿病护理(TNDM)的研究报告
- MarketBeat：回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性？
- 需要关注的2只半导体类股走势逆转
- 好市多盈利后价格疲软是买入的好时机吗？
- CrowdStrike是否会从增加每股收益指引中获得提振？
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
接受每日串联糖尿病护理的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Tandem糖尿病护理和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧